Krystal (KRYS) Reports Q1 2025 Earnings with Strong Revenue Growth
Krystal (KRYS) reported Q1 2025 earnings with net product revenue of $88.2 million for VYJUVEK, a 95% increase year-over-year. The company maintained a gross margin of 94%, while net income reached $35.7 million. The results highlight strong financial performance and preparation for European expansion.
Tickers: $KRYS
Topics: clinical programs earnings financial performance revenue stock compensation